Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Background Recent years have seen standardization of the anatomic definitions of
pancreatic adenocarcinoma, and increasing utilization of neoadjuvant therapy (NAT). The …

Simple Summary Borderline resectable pancreatic cancer (BRPC) has been primarily
indicated for neoadjuvant treatment (NAT) in the last decade. This study is the updated meta …

Background Pancreatic adenocarcinoma is a highly lethal malignancy. Neoadjuvant chemo
(radio) therapy [NAC (R) T] is recommended to use for borderline resectable pancreatic …

Abstract Purpose Locally advanced (T3/T4) gallbladder cancers with large fixed portal
nodes have a dismal prognosis. If undertaken, surgery entails extensive resections with high …

One of the main reasons for the dismal prognosis of pancreatic ductal adenocarcinoma
(PDAC) is its late diagnosis. At the time of presentation, only approximately 15–20% of all …

With the rapid development of imaging modalities and surgical techniques, the clinical entity
representing tumors that are intermediate between resectable and unresectable pancreatic …

Surgery is the only curative treatment for non-metastatic pancreatic adenocarcinoma, but
less than 20% of patients present a resectable disease at diagnosis. Treatment strategies …

Background Compared to the widely adopted 2–4 months of pre-operative therapy for
patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal …

The possibility of surgical resection strongly overrules medical oncologic treatment and is
the only modality, causa sine qua non, long-term survival can be achieved in patients with …